- Home
- ERH vs COEP Comparison
ERH vs COEP Comparison
Compare ERH & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ERH | COEP |
|---|---|---|
| Founded | 2004 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.7M | 100.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ERH | COEP |
|---|---|---|
| Price | $11.80 | $14.76 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 23.2K | ★ 97.1K |
| Earning Date | 01-01-0001 | 11-14-2025 |
| Dividend Yield | ★ 8.85% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $500,996.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.97 | $3.80 |
| 52 Week High | $10.91 | $21.41 |
Technical Indicators
Market Signals| Indicator | ERH | COEP |
|---|---|---|
| Relative Strength Index (RSI) | 43.69 | 49.91 |
| Support Level | $11.61 | $13.88 |
| Resistance Level | $11.95 | $15.12 |
| Average True Range (ATR) | 0.12 | 0.83 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 76.92 | 78.91 |
Price Performance
Historical ComparisonAbout ERH Allspring Utilities and High Income Fund
Allspring Utilities and High Income Fund is a diversified closed-end management investment company. Its investment objective is to seek a high level of current income and moderate capital growth, with an emphasis on providing tax-advantaged dividend income. The company allocates a majority of its total assets to a sleeve that places a focus on common, preferred, and convertible preferred stocks of utility companies and the rest of its total assets to a sleeve of U.S. dollar denominated below investment grade (high yield) debt.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.